Giant viruses encode protein-making tools for host control

A new study reveals that giant viruses, like the mimivirus, encode parts of the cellular protein-making machinery, allowing them to direct their amoeba hosts more effectively. This capability blurs the line between living and non-living entities. Researchers suggest it enhances viral production even under stressful conditions.

Giant viruses have intrigued biologists since 2003, when a mimivirus was identified in a water sample from Bradford, UK. This virus, which infects amoebae, is larger than many bacteria and features intricate structures along with hundreds of genes.

Typically, viruses depend on host cells to produce proteins, but some giant viruses incorporate elements of the translation machinery—the process that converts genetic information into proteins—directly into their genomes. Translation involves ribosomes and initiation complexes in cells.

Max Fels at Harvard Medical School and colleagues investigated this in infected amoebae. They isolated ribosomes from these cells and found associated viral proteins. “That was the first hint that they could be the factors we were looking for,” says Fels.

To test the role of these viral proteins, the team modified the virus's genes to prevent their production. This reduced viral output by up to 100,000-fold and severely limited new infectious particle formation.

The findings indicate that the viral complex redirects the host's protein-synthesis system toward producing viral proteins, functioning even during nutrient shortages or oxidative stress, which normally hinder host protein synthesis.

This raises evolutionary questions: did giant viruses evolve from ancient cells, or did they acquire genes from hosts? “Giant viruses have acquired a wide range of cellular machinery from their eukaryotic hosts throughout their evolution,” notes Frank Aylward at Virginia Tech, who was not involved in the study. Gene transfer during infections, followed by natural selection, likely preserved beneficial genes.

Such viruses target single-celled hosts like amoebae, where environments vary more than in multicellular organisms, making adaptable protein control advantageous.

The mimivirus genome codes for about 1,000 proteins, but most functions remain unknown, including precise regulation during infection cycles. “Viruses have long been considered rather passive entities in the evolution of living systems,” says Hiroyuki Ogata at Kyoto University in Japan. “This study shows that giant viruses can reshape molecular systems that are otherwise stably conserved across the domains of life.”

The research appears in Cell (DOI: 10.1016/j.cell.2026.01.008).

Related Articles

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
Image generated by AI

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

Reported by AI Image generated by AI Fact checked

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Researchers at the John Innes Centre have identified a three-gene system that causes bacteria to burst open, releasing virus-like particles that share DNA, including antibiotic resistance genes. The system, called LypABC, resembles a repurposed bacterial immune defense. The findings, published in Nature Microbiology, highlight how bacteria facilitate horizontal gene transfer.

Reported by AI

Researchers at the University of York have identified a protein called ESB2 that acts as a molecular shredder, enabling the African trypanosome parasite to evade the human immune system. The parasite, which causes sleeping sickness, uses ESB2 to precisely edit its genetic instructions in real time. This breakthrough solves a 40-year mystery in the parasite's biology.

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Reported by AI

Leading managers from the pharma and tech industries are raising alarms over potential misuse of AI and gene technology for biological weapons.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline